Community Bank N.A. raised its holdings in Pfizer, Inc. (NYSE:PFE) by 16.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,481 shares of the biopharmaceutical company’s stock after buying an additional 19,921 shares during the period. Community Bank N.A.’s holdings in Pfizer were worth $4,753,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of PFE. Dubuque Bank & Trust Co. increased its position in shares of Pfizer by 2.1% during the first quarter. Dubuque Bank & Trust Co. now owns 38,005 shares of the biopharmaceutical company’s stock worth $1,300,000 after purchasing an additional 768 shares in the last quarter. Delta Asset Management LLC TN increased its position in shares of Pfizer by 1.7% during the first quarter. Delta Asset Management LLC TN now owns 44,949 shares of the biopharmaceutical company’s stock worth $1,538,000 after purchasing an additional 769 shares in the last quarter. Duncker Streett & Co. Inc. increased its position in shares of Pfizer by 3.2% during the first quarter. Duncker Streett & Co. Inc. now owns 91,167 shares of the biopharmaceutical company’s stock worth $3,118,000 after purchasing an additional 2,796 shares in the last quarter. Court Place Advisors LLC increased its position in shares of Pfizer by 7.7% during the first quarter. Court Place Advisors LLC now owns 80,116 shares of the biopharmaceutical company’s stock worth $2,741,000 after purchasing an additional 5,728 shares in the last quarter. Finally, Adviser Investments LLC acquired a new stake in shares of Pfizer during the first quarter worth about $4,400,000. Institutional investors own 69.34% of the company’s stock.
PFE has been the topic of a number of research analyst reports. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG restated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. Pfizer has an average rating of “Hold” and a consensus target price of $38.48.
In other news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ian C. Read sold 197,168 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. Insiders have sold a total of 366,557 shares of company stock worth $12,532,406 in the last three months. Corporate insiders own 0.06% of the company’s stock.
Shares of Pfizer, Inc. (NYSE PFE) opened at $35.37 on Monday. The company has a market capitalization of $210,830.00, a P/E ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer, Inc. has a 52 week low of $30.51 and a 52 week high of $36.78.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 EPS. research analysts expect that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 78.53%.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/11/20/community-bank-n-a-has-4-75-million-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.